Somewhat Positive Media Coverage Somewhat Unlikely to Affect Zimmer Biomet Holdings (ZBH) Stock Price
News headlines about Zimmer Biomet Holdings (NYSE:ZBH) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet Holdings earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.2706600377328 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Zimmer Biomet Needs An Experienced Leader – Seeking Alpha (seekingalpha.com)
- Analyzing Inogen (INGN) and Zimmer Biomet Holdings (ZBH) (americanbankingnews.com)
- Zimmer Biomet Holdings Inc (ZBH) Pull in Gains For the Week – Financial News Review (finnewsreview.com)
- Is Zimmer Biomet Holdings, Inc. (ZBH) stock price is showing discouraging image with current unsupportive move of … – Stocks Gallery (stocksgallery.com)
- Gabelli Comments on Zimmer Biomet Holdings, Inc.’s FY2017 Earnings (ZBH) (americanbankingnews.com)
Zimmer Biomet Holdings (ZBH) opened at 113.01 on Thursday. The stock’s 50 day moving average price is $120.75 and its 200 day moving average price is $120.97. Zimmer Biomet Holdings has a 52 week low of $95.63 and a 52 week high of $133.49. The firm has a market cap of $22.85 billion, a price-to-earnings ratio of 32.19 and a beta of 1.20.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.02 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings will post $8.24 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.
ZBH has been the subject of a number of research analyst reports. Oppenheimer Holdings, Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Monday, August 14th. BidaskClub cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Gabelli began coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price objective on the stock. Canaccord Genuity restated a “buy” rating and set a $141.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Finally, BMO Capital Markets boosted their price objective on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $136.75.
In related news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.